Moxquin 400: Each film coated tablet contains Moxifloxacin Hydrochloride USP equivalent to Moxifloxacin 400 mg.
Moxquin 400 mg IV infusion : Each bottle contains 250 ml solution containing Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 400 mg.
Moxifloxacin is a synthetic broad spectrum, flouroquinolone derivative antibacterial agent. Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bactericidal action of Moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
Moxifloxacin is indicated for the treatment of adults (>18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below-
- Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae or Moraxella
- Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus
influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus or
- Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains),
Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella
pneumoniae, Mycoplasma pneumoniae or Chlamydophilia pneumoniae
- Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or
- Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus,
Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae
- Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by
Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis,
Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron or Peptostreptococcus species.
• The dose of Moxifloxacin is 400 mg once every 24 hours. The duration of therapy depends on the type of infection as described bellow-
• In Acute Bacterial Sinusitis Moxifloxacin 400 mg is given once daily for 10 days.
• In Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin 400 mg is given once daily for 5 days.
• In Community Acquired Pneumonia Moxifloxacin 400 mg is given once daily for 7-14 days.
• In Uncomplicated Skin & Skin Structure infections Moxifloxacin 400 mg is given once daily for 7 days.
• In Complicated Skin & Skin Structure infections Moxifloxacin 400 mg is given once daily for 7-21 days.
• In Complicated Intra-Abdominal infections Moxifloxacin 400 mg is given once daily for 5-14 days.
Moxquin 400 mg IV infusion can be administered intravenously for the entire treatment duration. Alternatively, therapy may be initial intravenous administration, followed by oral administration when clinically indicated. The recommended duration of treatment for the indication being treated should not be exceeded. The solution for infusion should be infused intravenously over 60 minutes.
No adjustment of dosage is required in the elderly.
Efficacy and safety of Moxquin IV infusion in children and adolescent have not been established.
The following one or more side effects may be observed: tendinopathy and tendon rupture, QT prolongation, hypersensitivity reactions, clostridium difficile-associated diarrhea, peripheral neuropathy, photosensitivity, phototoxicity etc.
Moxifloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Moxifloxacin should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon.
Pregnancy Category C. Moxifloxacin is not recommended during pregnancy & lactation.
No quinolone should be co-administered with any solution containing multivalent cations (e.g. magnesium) through the same intravenous line. Antacids, iron and adsorbents reduce absorption of Moxifloxacin. NSAID may increase the risk of CNS stimulation. Warfarin may increase the risk of bleeding.
In the events of an acute overdosage, the stomach should be emptied. The patients should be kept under observation and appropriate hydration should be maintained.
Do not store above 30 C. Keep away from light and out of the reach of children.
IV infusion: Do not refrigerate. Check the bottle against a light source prior to administration. Do not use if the solution is turbid or contains particles. Discard any unused portion.
Moxquin 400: Each box contains 3 blister strips of 4 tablets.
Moxquin 400 mg IV infusion: Each box contains a bottle of 250 ml solution, a bottle hanger and an infusion set.